1. Home
  2. CENT vs DFTX Comparison

CENT vs DFTX Comparison

Compare CENT & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Garden & Pet Company

CENT

Central Garden & Pet Company

N/A

Current Price

$36.56

Market Cap

2.4B

ML Signal

N/A

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$17.99

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CENT
DFTX
Founded
1955
N/A
Country
United States
United States
Employees
6000
N/A
Industry
Consumer Specialties
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CENT
DFTX
Price
$36.56
$17.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$50.00
$40.25
AVG Volume (30 Days)
58.5K
1.4M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.60
N/A
Revenue Next Year
$2.04
N/A
P/E Ratio
$15.73
N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.77
$14.62
52 Week High
$41.25
$19.62

Technical Indicators

Market Signals
Indicator
CENT
DFTX
Relative Strength Index (RSI) 44.15 54.04
Support Level $34.52 $16.26
Resistance Level $38.34 $18.21
Average True Range (ATR) 0.90 0.94
MACD -0.49 0.11
Stochastic Oscillator 12.08 46.93

Price Performance

Historical Comparison
CENT
DFTX

About CENT Central Garden & Pet Company

Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: